- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05634447
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391
October 5, 2023 updated by: Chong Kun Dang Pharmaceutical
A Phase I Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-391 and Co-administration of CKD-331 and D337 in Healthy Adult Volunteers
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-391
Study Overview
Detailed Description
A phase I clinical trial to compare and evaluate the safety and pharmacokinetic characteristics after administration of CKD-391 and co-administration of CKD-331 and D337 in healthy adult volunteers
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hyeon Soo Park, M.D.
- Phone Number: +82-10-6455-2016
- Email: wefe6405@bumin.co.kr
Study Locations
-
-
Gangseo-gu
-
Seoul, Gangseo-gu, Korea, Republic of, 07590
- Bumin Hospital(Seoul)
-
Contact:
- Hyeon Soo Park, M.D.
- Phone Number: +82-10-6455-2016
- Email: wefe6405@bumin.co.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy adult aged between 19 to 55 at screening
- Weight ≥ 50kg(man) or 45kg(woman), with calculated body mass index (BMI) of 18 to 30kg/m2
- Those who have no clinically significant congenital or chronic diseases and have no abnormal symptoms of findings
- Those who are deemed suitable for clinical trials based on laboratory (hematology, blood chemistry, serology, urinalysis, urine drug test) and 12-lead ECG results at screening
- Those who agree to contraception from the first IP dosing day till 14 days after the last dosing day and decide not to provide sperm during the participation of clinical trial
- Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial
Exclusion Criteria:
- Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day
- Those who exceed an alcohol, caffeine and cigarette consumption (caffeine> 5 cups/day, alcohol> 21 glasses/week(man), 14 glasses/week(woman), smoking> 20 cigarettes/day) and not able to stop on smoking, caffeine and alcohol
- Those who received investigational products or participated in bioequivalence test within 6 months before the first administration of clinical trial drugs
- Those who donated whole blood within 8 weeks before the first date of administration and donated ingredients within 2 weeks or received blood transfusion in 4 weeks
- Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery
Patients with the following diseases
- Patients with active liver disease or with elevated amino transferase levels with unknown cause increased by more than 3 times the normal upper limit
- Patients with severe liver failure or biliary obstruction and bile congestion
- Patients with muscular disease, rhabdomyolysis, or persons with a past history
- Patients with hypothyroidism, patients with genetic muscle disease or their family history, and patients with history of muscle disability due to drugs
- Patients with renal impairment or a history of in and patients with severe renal dysfunction
- Patients with a history of muscle toxicity to other statin drugs or fibrate drugs
- Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Those who have hypersensitivity to the main constituents or components of the investigational drug
- Those who have a history of drug abuse within 1 year of screening or who have tested positive for urine drug tests
- Woman who are pregnant or breastfeeding
- Those who are deemed insufficient to participate in clinical study by investigators
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1
|
Drug: CKD-331, D337 QD, PO
|
Experimental: Sequence 2
|
Drug: CKD-331, D337 QD, PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Outcome Measure
Time Frame: Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours
|
AUCt of CKD-391: Area under the concentration-time curve time zero to time
|
Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours
|
Primary Outcome Measure
Time Frame: Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours
|
Cmax of CKD-391: Maximum plasma concentration of the drug
|
Pre-dose(0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 20, 2022
Primary Completion (Actual)
February 27, 2023
Study Completion (Actual)
June 7, 2023
Study Registration Dates
First Submitted
November 22, 2022
First Submitted That Met QC Criteria
November 22, 2022
First Posted (Actual)
December 2, 2022
Study Record Updates
Last Update Posted (Actual)
October 6, 2023
Last Update Submitted That Met QC Criteria
October 5, 2023
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A52_10BE2220
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidemias
-
IlDong Pharmaceutical Co LtdCompletedMixed DyslipidemiasKorea, Republic of
-
Orient Pharma Co., Ltd.CompletedPrimary Hypercholesterolemia | Mixed DyslipidemiasTaiwan, Australia, New Zealand
-
AstraZenecaAstraZeneca K.K.RecruitingDyslipidemiaDenmark, Hungary, Spain, United States, Japan, Czechia, Slovakia, Canada
-
Yonsei UniversityRecruitingClinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With DyslipidemiaDyslipidemiaKorea, Republic of
-
Dongkwang Pharm. Co., Ltd.Not yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingDyslipidemias
-
Hospices Civils de LyonRecruiting
-
AmgenCompletedDyslipidemiaUnited States, Poland, Czechia, Hungary, Russian Federation, Ukraine, Slovakia
-
Sun Yat-sen UniversityCompleted
Clinical Trials on Drug: CKD-391, QD, PO
-
Chong Kun Dang PharmaceuticalCompletedType II DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalNot yet recruitingType II Diabetes Mellitus
-
Chong Kun Dang PharmaceuticalSeoul National University Bundang HospitalCompleted
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiasKorea, Republic of
-
Chong Kun Dang PharmaceuticalActive, not recruiting
-
Kind Pharmaceuticals LLCRecruitingAdvanced or Metastatic Breast CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingWarm Antibody Autoimmune Hemolytic AnemiaChina
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
TYK Medicines, IncCompleted